SpyGlass Pharma has successfully secured $75 million in Series D financing to support its innovative Drug Delivery Platform. The company’s CEO, Mooney, expressed gratitude for the strong support from both new and existing investors, highlighting their confidence in the platform. This funding will facilitate the advancement of SpyGlass Pharma’s platform through pivotal phase 3 trials, […]